STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £55.86m
- £68.28m
- $49.70m
Brief: Shield Therapeutics Says Korean Partner Files NDA For Accrufer In Republic Of Korea
Shield Therapeutics - New Drug Application for Accrufer® in South Korea
Shield Therapeutics - Audited results for the year ended 31 Dec 2023
Brief: Shield Therapeutics Reaffirms Cashflow Outlook
Shield Therapeutics - Business Update for Q1 2024
Shield Therapeutics - Notice of Results
Brief: Shield Therapeutics Says FY Total Revenue And Other Income Of $17.5 Mln
Shield Therapeutics - Unaudited Full Year Trading Update
Brief: Shield Therapeutics Appoints Santosh Shanbhag As CFO
Shield Therapeutics - Appointment of new Chief Financial Officer
Brief: Shield Therapeutics Says Total Q3 2023 U.S. Net Revenue Of $4.1 MLN
Shield Therapeutics - Q3 2023 U.S. Commercial Highlights
Shield Therapeutics - PDMR Transaction Notification
RCS - Shield Therapeutics - Abstract to be presented at Healthcare Conference
Brief: Shield Therapeutics PLC Says Hans-Peter Rudolf Is Standing Down From His Role As CFO Of Group
Cavendish Financial - AGM Trading Statement
Shield Therapeutics - Successful completion of US$6.1m Equity Fundraise
Brief: Shield Therapeutics Announces REX Retail Offer Of Up To £1.1 Mln Of New Ordinary Shares Of 1.5 Pence
Brief: Shield Therapeutics Says H1 Revenue $4.3 Mln Vs $2.6 Mln Year Ago